Sustiva — Competitive Intelligence Brief

Sustiva (EFAVIRENZ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]. Area: Immunology.

marketed Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Cholesterol 24-hydroxylase Immunology Small molecule

Target snapshot

Sustiva (EFAVIRENZ) — Bristol-Myers Squibb. Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sustiva TARGET	EFAVIRENZ	Bristol-Myers Squibb	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Cholesterol 24-hydroxylase	1998-01-01
Sustiva	Sustiva	Bristol-Myers Squibb	marketed		Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Intelence	ETRAVIRINE	Janssen R And D	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Canalicular multispecific organic anion transporter 2	2008-01-01
Rescriptor	DELAVIRDINE	GSK	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor	Histamine H4 receptor	1997-01-01
Viramune	NEVIRAPINE	Boehringer Ingelheim	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		1996-01-01
Efavirenz, lamivudine, and tenofovir	Efavirenz, lamivudine, and tenofovir	University of Maryland, Baltimore	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-03-12 — Viramune · 8460704 · Method of Use · US

Sponsor landscape (Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class)

1. Boehringer Ingelheim · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Janssen R And D · 1 drug in this class
4. Merck & Co. · 1 drug in this class
5. University of Maryland, Baltimore · 1 drug in this class
6. University of North Carolina, Chapel Hill · 1 drug in this class